AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7714943 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam (1 g ampicillin/0.5 g sulbactam) plus 1 g probenecid orally
Number of subjects: 330
Study 7714943 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone (250 mg)
Number of subjects: 330
Study 7714943 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 330
Study 7714943 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 330
Study 2720576 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate tablets (MS Contin) given every 12 hours
Number of subjects: 23
Study 2720576 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine sulfate solution (MSS) given every 4 hours
Number of subjects: 23
Study 2720576 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate tablets (MS Contin) given every 8 hours
Number of subjects: 23
Study 311410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 56
Study 311410 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 56
Study 311410 — intervention group
Group type: COMPARATOR
Intervention: No anticandidal prophylaxis (Control)
Number of subjects: 56
Study 31283676 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical presentations of information regarding transplant rates
Number of subjects: 975
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care provider letters
Number of subjects: 276
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard mailings
Number of subjects: 276
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook posts
Number of subjects: 276
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Family and friends referrals
Number of subjects: 276
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper or television
Number of subjects: 276
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ads
Number of subjects: 276
Study 30829836 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ads and postcard mailings
Number of subjects: 276
Study 28355890 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about thoughts and feelings specific to lymphedema and its treatment
Number of subjects: 107
Study 28355890 — intervention group
Group type: COMPARATOR
Intervention: Writing about daily activities (control)
Number of subjects: 107
Study 25583588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi aquatic therapy programme
Number of subjects: 20
Study 23338547 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized and supervised exercise program for pelvic floor muscles (PFM), 8 weeks, twice a week
Number of subjects: 23
Study 23338547 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no exercise recommendations)
Number of subjects: 23
Study 23338547 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment methods: digital vaginal palpation and perineometer
Number of subjects: 23
Study 21839816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 14
Study 21839816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg.kg(‐1)
Number of subjects: 165
Study 19143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg.kg(‐1)
Number of subjects: 165
Study 19143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg.kg(‐1)
Number of subjects: 165
Study 19143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.5 mg.kg(‐1)
Number of subjects: 165
Study 19143690 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 165
Study 17288323 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with Clearfil ST resin composite (SE)
Number of subjects: 20
Study 17288323 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond with A110 resin composite (SB)
Number of subjects: 20
Study 17288323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (FJ)
Number of subjects: 20
Study 15481276 — intervention group
Group type: EXPERIMENTAL
Intervention: R-salbutamol (0.63 mg inhaled three times daily for 1 week)
Number of subjects: 26
Study 15481276 — intervention group
Group type: COMPARATOR
Intervention: R,S-salbutamol (1.25 mg inhaled three times daily for 1 week)
Number of subjects: 26
Study 11915302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% phosphorylated chitosan mouth rinse
Number of subjects: 3
Study 11915302 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinsing
Number of subjects: 3
Study 9272411 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet administered as an infusion twice daily (BID)
Number of subjects: 12
Study 9272411 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet administered as an infusion thrice daily (TID)
Number of subjects: 12
Study 7935029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated oestrogens (oCE) + dydrogesterone (DYDR)
Number of subjects: 2
Study 7935029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated oestrogens (oCE) + norethisterone acetate (NETA)
Number of subjects: 2
Study 7935029 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (tdE2) + dydrogesterone (DYDR)
Number of subjects: 2
Study 3286509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (1,000 mg daily)
Number of subjects: 51
Study 3286509 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg daily)
Number of subjects: 51
Study 31336212 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Mix (1.8ml 2% lignocaine with 1:200,000 epinephrine and 1ml/4mg dexamethasone)
Number of subjects: 20
Study 31336212 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Twin Mix (1.7ml of 4% articaine with 1:100,000 epinephrine and 1ml/4mg dexamethasone)
Number of subjects: 20
Study 31336212 — intervention group
Group type: COMPARATOR
Intervention: Control (1.8ml of 2% lignocaine with 1:200,000 adrenaline)
Number of subjects: 20
Study 31336212 — intervention group
Group type: COMPARATOR
Intervention: Control (1.7ml of 4% articaine with 1:100,000 adrenaline)
Number of subjects: 20
Study 30784356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol or codeine
Number of subjects: 102
Study 27362908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted vasopressin solution (20 U in 400 ml normal saline)
Number of subjects: 152
Study 27362908 — intervention group
Group type: COMPARATOR
Intervention: Concentrated vasopressin solution (20 U in 60 ml normal saline)
Number of subjects: 152
Study 25464058 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who exerted self-control before a taste test of unhealthy food
Number of subjects: 0
Study 25464058 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participants who did not exert self-control)
Number of subjects: 0
Study 25464058 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived successful weight regulators
Number of subjects: 0
Study 25464058 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived unsuccessful self-regulators
Number of subjects: 0
Study 23775057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 320 mg/d
Number of subjects: 75
Study 23775057 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 160 mg/d
Number of subjects: 75
Study 21911976 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment group (amoxicillin, clarithromycin, omeprazole for 2 weeks)
Number of subjects: 40
Study 21911976 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study 19934241 — intervention group
Group type: EXPERIMENTAL
Intervention: One tooth bleaching (35% hydrogen peroxide enabled by LEDs)
Number of subjects: 72
Study 19934241 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tooth bleachings interspersed by aging
Number of subjects: 72
Study 19934241 — intervention group
Group type: COMPARATOR
Intervention: No bleaching (control group)
Number of subjects: 72
Study 17214750 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (12-week program)
Number of subjects: 38
Study 17214750 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control condition
Number of subjects: 38
Study 15562881 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 52
Study 15562881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15562881 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 52
Study 11573520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (HD group: 0.08 mg kg(‐1) bolus and 0.08 mg kg(‐1) h(‐1) continuous infusion)
Number of subjects: 248
Study 11573520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (LD group: 0.04 mg kg(‐1) bolus and 0.04 mg kg(‐1) h(‐1) continuous infusion)
Number of subjects: 248
Study 11573520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 248
Study 10452064 — intervention group
Group type: EXPERIMENTAL
Intervention: Escharectomy during burn shock stage
Number of subjects: 60
Study 7934434 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwashed breast
Number of subjects: 30
Study 7934434 — intervention group
Group type: COMPARATOR
Intervention: Washed breast
Number of subjects: 30
Study 2896870 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum P3NP levels
Number of subjects: 63
Study 2896870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox multivariate analysis of serum P3NP
Number of subjects: 63
Study 2896870 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations with serum P3NP
Number of subjects: 63
Study 2896870 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised P3NP levels
Number of subjects: 63
Study 2896870 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum P3NP
Number of subjects: 63
Study 31973702 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianxiety Granule
Number of subjects: 0
Study 31973702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28819993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus-fermented milk drink (190 g/day)
Number of subjects: 0
Study 28819993 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (equivalent amount)
Number of subjects: 0
Study 28248054 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel for 12 weeks postoperatively)
Number of subjects: 60
Study 28248054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no testosterone replacement therapy)
Number of subjects: 60
Study 28248054 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel)
Number of subjects: 60
Study 25557125 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol‐remifentanil (group PR)
Number of subjects: 50
Study 25557125 — intervention group
Group type: COMPARATOR
Intervention: propofol‐ketamine (group PK)
Number of subjects: 50
Study 24304332 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil penile injections (12 total injections for six months and subsequently every month for twelve months: total 24 injections) + Iontophoresis with Verapamil/daily + blueberries 160mg/daily + propolis 600mg/daily + Vitamin E 600mg/daily + topical Diclofenac/daily
Number of subjects: 82
Study 24304332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82
Study 24304332 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil penile injections (and associated treatments)
Number of subjects: 82
Study 19802506 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training exercises plus risedronate, calcium, and vitamin D
Number of subjects: 223
Study 19802506 — intervention group
Group type: COMPARATOR
Intervention: Risedronate, calcium, and vitamin D only
Number of subjects: 223
Study 19802506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to exercise (≥50%)
Number of subjects: 223
Study 18157071 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g daily for 60 days
Number of subjects: 73
Study 18157071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16877730 — intervention group
Group type: COMPARATOR
Intervention: Letrozole (2.5 mg daily for 6 months)
Number of subjects: 114
Study 16877730 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus oral cyclophosphamide (50 mg daily for 6 months)
Number of subjects: 114
Study 16877730 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole plus oral cyclophosphamide
Number of subjects: 114
Study 12940940 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose supplementation during exercise
Number of subjects: 6
Study 12940940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no glucose supplementation) during exercise
Number of subjects: 6
Study 10711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aqueous suppressants
Number of subjects: 41
Study 10711900 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical aqueous suppressants)
Number of subjects: 41
Study 9010961 — intervention group
Group type: EXPERIMENTAL
Intervention: human corticotropin releasing factor (hCRF)
Number of subjects: 10
Study 9010961 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRF/naloxone
Number of subjects: 10
Study 9010961 — intervention group
Group type: EXPERIMENTAL
Intervention: combined multifaceted 5-min stress test
Number of subjects: 10
Study 9010961 — intervention group
Group type: EXPERIMENTAL
Intervention: novelty-related anticipation
Number of subjects: 10
Study 9010961 — intervention group
Group type: EXPERIMENTAL
Intervention: age-related differences in AVP levels
Number of subjects: 10
Study 1390121 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (0.6 mg/kg)
Number of subjects: 39
Study 1390121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methoxypsoralen (1.2 mg/kg)
Number of subjects: 39
Study 4005392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablets containing 40 mg isosorbide dinitrate
Number of subjects: 12
Study 4005392 — intervention group
Group type: COMPARATOR
Intervention: Reference standard-release tablets containing 20 mg isosorbide dinitrate
Number of subjects: 12
Study 31545577 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 15 cmH2O
Number of subjects: 66
Study 31545577 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 10 cmH2O
Number of subjects: 66
Study 31545577 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 12 cmH2O
Number of subjects: 66
Study 30497497 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundnut production constraints assessment through participatory rural appraisal approach
Number of subjects: 180
Study 30497497 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmers' trait preferences assessment
Number of subjects: 180
Study 27243900 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence (pill count coverage)
Number of subjects: 1785
Study 27243900 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence (plasma tenofovir levels)
Number of subjects: 1785
Study 24737199 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of 1,25(OH)2D
Number of subjects: 1151
Study 24737199 — intervention group
Group type: COMPARATOR
Intervention: Second tertile of 1,25(OH)2D
Number of subjects: 1151
Study 24737199 — intervention group
Group type: COMPARATOR
Intervention: Third tertile of 1,25(OH)2D
Number of subjects: 1151
Study 21831487 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 0.5% ropivacaine
Number of subjects: 40
Study 21831487 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with 1:200,000 adrenaline
Number of subjects: 40
Study 21831487 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:100,000 adrenaline
Number of subjects: 40
Study 21831487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with adrenaline
Number of subjects: 40
Study 21831487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline
Number of subjects: 40
Study 21831487 — intervention group
Group type: COMPARATOR
Intervention: All groups tested
Number of subjects: 40
Study 20929609 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SFC) 50 μg/100 μg b.i.d.
Number of subjects: 24
Study 20929609 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP) 200 μg b.i.d.
Number of subjects: 24
Study 20929609 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SFC)
Number of subjects: 24
Study 20929609 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP)
Number of subjects: 24
Study 20929609 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SFC) and Fluticasone Propionate (FP)
Number of subjects: 24
Study 18621797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 50
Study 18621797 — intervention group
Group type: COMPARATOR
Intervention: 8‐0 Vicryl sutures
Number of subjects: 50
Study 15823204 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Walk Rounds (EWRs)
Number of subjects: 283
Study 15823204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EWR participation)
Number of subjects: 283
Study 15823204 — intervention group
Group type: EXPERIMENTAL
Intervention: EWRs
Number of subjects: 283
Study 12821239 — intervention group
Group type: EXPERIMENTAL
Intervention: rNAPc2 at 3.5 microg/kg
Number of subjects: 154
Study 12821239 — intervention group
Group type: EXPERIMENTAL
Intervention: rNAPc2 at 5.0 microg/kg
Number of subjects: 154
Study 12821239 — intervention group
Group type: EXPERIMENTAL
Intervention: rNAPc2 at 7.5 microg/kg
Number of subjects: 154
Study 12821239 — intervention group
Group type: EXPERIMENTAL
Intervention: rNAPc2 at 10.0 microg/kg
Number of subjects: 154
Study 12821239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 10620633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 10620633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8656173 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 1386374 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa with norethindrone 5 then 10 mg daily
Number of subjects: 20
Study 1386374 — intervention group
Group type: COMPARATOR
Intervention: GnRHa alone (placebo group)
Number of subjects: 20
Study 6693601 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-application of topical medication
Number of subjects: 29
Study 6693601 — intervention group
Group type: COMPARATOR
Intervention: Application by a trained attendant
Number of subjects: 29
Study 6693601 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-application of fluorescent sunscreen
Number of subjects: 29
Study 6693601 — intervention group
Group type: COMPARATOR
Intervention: Cream vs ointment
Number of subjects: 29
Study 6693601 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic liquid vs creamy liquid
Number of subjects: 29
Study 31627089 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple fixed-dose combination (TFC) therapy of perindopril/indapamide/amlodipine
Number of subjects: 92
Study 31627089 — intervention group
Group type: COMPARATOR
Intervention: Triple free combination therapy (FCT) including ACEI/diuretic/CCB
Number of subjects: 92
Study 29357380 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led structured patient education (n = 76)
Number of subjects: 151
Study 29357380 — intervention group
Group type: COMPARATOR
Intervention: Conventional care alone (n = 75)
Number of subjects: 151
Study 26155765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg, twice daily during 12 weeks of chemotherapy
Number of subjects: 46
Study 26155765 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily during 12 weeks of chemotherapy
Number of subjects: 46
Study 26155765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 46
Study 26155765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24646102 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3 daily (group B)
Number of subjects: 193
Study 24646102 — intervention group
Group type: COMPARATOR
Intervention: Routine care (200 mg ferrous sulfate and 600 mg calcium daily, group A)
Number of subjects: 193
Study 24646102 — intervention group
Group type: COMPARATOR
Intervention: Routine care (group A)
Number of subjects: 193
Study 23302671 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol, 20 mg/d, n = 36
Number of subjects: 72
Study 23302671 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two tablets/d, n = 36
Number of subjects: 72
Study 19913351 — intervention group
Group type: EXPERIMENTAL
Intervention: FL cystoscopy
Number of subjects: 300
Study 19913351 — intervention group
Group type: COMPARATOR
Intervention: WL cystoscopy
Number of subjects: 300
Study 17697309 — intervention group
Group type: EXPERIMENTAL
Intervention: G-TIVA-TEA (Total Intravenous Anesthesia with Thoracic Epidural Anaesthesia)
Number of subjects: 100
Study 17697309 — intervention group
Group type: EXPERIMENTAL
Intervention: G-TIVA (Total Intravenous Anesthesia without Thoracic Epidural Anaesthesia)
Number of subjects: 100
Study 17697309 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ISO-TEA (Isoflurane Anaesthesia with Thoracic Epidural Anaesthesia)
Number of subjects: 100
Study 17697309 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ISO (Isoflurane Anaesthesia without Thoracic Epidural Anaesthesia)
Number of subjects: 100
Study 15258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Han men
Number of subjects: 5887
Study 15258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Han women
Number of subjects: 5887
Study 15258131 — intervention group
Group type: COMPARATOR
Intervention: Tibetan men
Number of subjects: 5887
Study 15258131 — intervention group
Group type: COMPARATOR
Intervention: Tibetan women
Number of subjects: 5887
Study 15258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall gender-related difference
Number of subjects: 5887
Study 15258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood to young adulthood
Number of subjects: 5887